Sangamo Therapeutics Inc (SGMO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by the publisher to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
Aug 04, 2022: Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2022 Financial Results
Jun 01, 2022: Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences
May 02, 2022: Sangamo Therapeutics to present data from its next-generation technologies at 2022 Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
The profile contains critical company information including:
- Business description - A detailed description of the company's operations and business divisions.
- Corporate strategy - Analyst's summarization of the company's business strategy.
- SWOT Analysis - A detailed analysis of the company's strengths, weakness, opportunities and threats.
- Company history - Progression of key events associated with the company.
- Major products and services - A list of major products, services and brands of the company.
- Key competitors - A list of key competitors to the company.
- Key employees - A list of the key executives of the company.
- Executive biographies - A brief summary of the executives' employment history.
- Key operational heads - A list of personnel heading key departments/functions.
- Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights
Sangamo Therapeutics Inc (Sangamo), formerly Sangamo BioSciences Inc, is a biotechnology company that focuses on the research, development, and commercialization of engineered DNA-binding protein Zinc Finger Transcription (ZFPs). Its ZFPs candidates are based on its proprietary gene therapy technologies. It is advancing its pipeline candidates for the treatment of HIV/AIDS, hemophilia A and B, hurler syndrome (MPS I), Huntington's disease, Fabry disease, Alzheimer's disease, and many others. Its ZFPs based products are used in various applications such as human therapeutics, research reagents, pharmaceutical protein production, plant agriculture, cell-line engineering, and production of transgenic animals. Sangamo is headquartered in Brisbane, California, the US.Sangamo Therapeutics Inc Key Recent Developments
Apr 27, 2023: Sangamo Therapeutics announces strategic update and reports preliminary First Quarter 2023 financial resultsAug 04, 2022: Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2022 Financial Results
Jun 01, 2022: Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences
May 02, 2022: Sangamo Therapeutics to present data from its next-generation technologies at 2022 Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.- The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
- The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Table of Contents
Section 1 - About the Company
Section 2 - Company Analysis
Section 3 - Company Financial Ratios
Section 4 - Company’s Lifesciences Financial Deals and Alliances
Section 5 - Company’s Recent Developments
Section 6 - Appendix
List of Tables
List of Figures
Samples
LOADING...
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Acceleron Pharma Inc
- Lyell Immunopharma Inc
- Genzyme Corp
- BioMarin Pharmaceutical Inc
- Editas Medicine Inc
- Amgen Inc
- Taysha Gene Therapies Inc
- Pfizer Inc
- Merck & Co Inc
- GSK plc
- Sigilon Therapeutics Inc
- Precision Biosciences Inc
- Novo Nordisk Inc
- Novartis Corp
- Genentech USA Inc
- Beam Therapeutics Inc
- Lyell Immunopharma Inc
- Genzyme Corp
- Taysha Gene Therapies Inc
- Pfizer Inc
- Merck & Co Inc
- GSK plc
- Genentech USA Inc
- Novo Nordisk Inc
- Acceleron Pharma Inc
- Sigilon Therapeutics Inc
- Precision Biosciences Inc
- Editas Medicine Inc
- Amgen Inc
- Novartis Corp
- Beam Therapeutics Inc
- BioMarin Pharmaceutical Inc